Report cover image

Developmental and Epileptic Encephalopathies Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

Publisher BIS Research
Published Oct 15, 2025
SKU # BIS20470591

Description

Global Developmental and Epileptic Encephalopathies Market: Overview

The global developmental and epileptic encephalopathies market is projected to expand significantly from 2024 to 2035, reflecting a steady compound annual growth rate (CAGR) over the forecast period. This growth is primarily fueled by the increasing incidence of developmental and epileptic encephalopathies, particularly among children, which is driving heightened awareness and a growing demand for effective treatments. Additionally, advancements in treatment options are enhancing patient care and facilitating more effective treatment.

Developmental and epileptic encephalopathies are a group of severe, often debilitating neurological disorders marked by developmental delays, intellectual disabilities, and refractory epilepsy. Recent advancements, including gene therapies such as CRISPR and neurostimulation devices like responsive neurostimulation (RNS), are offering new and promising treatment options for these conditions.

Market Lifecycle Stage

The market for developmental and epileptic encephalopathies treatments is in a rapidly evolving phase, transitioning from symptomatic management to more targeted, disease-modifying therapies. While current treatments primarily focus on managing seizures, the emphasis is now shifting toward gene therapy, precision medicine, and personalized treatment approaches that address the root causes of developmental and epileptic encephalopathies. The emergence of new, more effective drug formulations and biologics is expected to transform the therapeutic landscape significantly in the global developmental and epileptic encephalopathies market.

North America is expected to maintain its dominant position in the global developmental and epileptic encephalopathies market, driven by a well-established healthcare infrastructure, a high rate of diagnosis, and ongoing investment in research and development for rare neurological disorders.

Demand – Drivers and Limitations

The global developmental and epileptic encephalopathies market is driven by several key factors:

Gene therapies are providing new treatment options
Rising cases of developmental and epileptic encephalopathies, particularly in children, are driving greater awareness and demand for treatments.

Limitations:

Limited access to advanced treatments in low-income regions due to economic and healthcare infrastructure limitations
Expensive research and high clinical trial failure rates discourage investment in therapies for developmental and epileptic encephalopathies.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report helps companies identify opportunities to innovate in developmental and epileptic encephalopathies treatments, focusing on genetic therapies, personalized medicine, and biologics that target specific molecular pathways in developmental and epileptic encephalopathies patients.

Competitive Strategy: Pharmaceutical companies and healthcare providers can leverage the insights provided in this report to assess current market dynamics, emerging trends, and key players to develop strategic approaches to stay competitive in the global developmental and epileptic encephalopathies market.

Key Market Players and Competition Synopsis

The companies profiled in this report are selected based on expert insights, evaluating company coverage, product portfolio, and market penetration. Leading players in the global developmental and epileptic encephalopathies market include pharmaceutical companies that hold substantial shares of the market.

Some of the prominent names established in this market are:

Harmony Biosciences
Longboard Pharmaceuticals (Subsidiary of Lundbeck)
Neurocrine Biosciences
Encoded Therapeutics
Ovid Therapeutics
Takeda Pharmaceutical Company Limited

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Table of Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria
1. Global Developmental and Epileptic Encephalopathies Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis of Global Developmental and Epileptic Encephalopathies
1.3 Market Trends
1.4 Clinical Trials Analysis
1.5 Regulatory Landscape Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Developmental and Epileptic Encephalopathies Market (by Region)
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Developmental and Epileptic Encephalopathies Market (by Country)
2.1.2.1.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Developmental and Epileptic Encephalopathies Market (by Country)
2.2.2.1.1 Germany
2.2.2.1.2 France
2.2.2.1.3 U.K.
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Developmental and Epileptic Encephalopathies Market (by Country)
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. Global Developmental and Epileptic Encephalopathies Market - Competitive Benchmarking and Company Profiles
3.1 Key Strategies and Developments by Company
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Harmony Biosciences
3.2.1.1 Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers
3.2.1.4 Key Personnels
3.2.1.5 Analyst View
3.2.2 Longboard Pharmaceuticals (Subsidiary of Lundbeck)
3.2.2.1 Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers
3.2.2.4 Key Personnels
3.2.2.5 Analyst View
3.2.3 Takeda Pharmaceutical Company Limited
3.2.3.1 Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers
3.2.3.4 Key Personnels
3.2.3.5 Analyst View
3.2.4 Neurocrine Biosciences
3.2.4.1 Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers
3.2.4.4 Key Personnels
3.2.4.5 Analyst View
3.2.5 Encoded Therapeutics, Inc.
3.2.5.1 Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers
3.2.5.4 Key Personnels
3.2.5.5 Analyst View
3.2.6 Ovid Therapeutics
3.2.6.1 Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers
3.2.6.4 Key Personnels
3.2.6.5 Analyst View
3.2.7 Others
4. Research Methodology
List of Figures
Figure: Global Developmental and Epileptic Encephalopathies Market, 2024 and 2035
Figure: Global Developmental and Epileptic Encephalopathies Market, Market Dynamics
Figure: Global Developmental and Epileptic Encephalopathies Market Coverage
Figure: Global Developmental and Epileptic Encephalopathies Market Key Trends, Impact Analysis
Figure: Global Developmental and Epileptic Encephalopathies Market, Competitive Landscape
Figure: North America Developmental and Epileptic Encephalopathies Market, $Million, 2024-2035
Figure: Europe Developmental and Epileptic Encephalopathies Market, $Million, 2024-2035
Figure: Asia-Pacific Developmental and Epileptic Encephalopathies Market, $Million, 2024-2035
List of Tables
Table: Market Snapshot
Table: Global Developmental and Epileptic Encephalopathies Market, Comparative Analysis
Table: Global Developmental and Epileptic Encephalopathies Market, Regulatory Scenario
Table: Global Developmental and Epileptic Encephalopathies Market Dynamics, Impact Analysis
Table: Global Developmental and Epileptic Encephalopathies Market, (by Region), $Million, 2024-2035

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us